DNA Damage Response in Early Breast Cancer: A Phase III Cohort in the Phobos Study DOI Open Access
Eriseld Krasniqi, Cristiana Ercolani, Anna Di Benedetto

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(15), P. 2628 - 2628

Published: July 23, 2024

We assessed the impact of DNA damage response and repair (DDR) biomarker expressions in 222 node-positive early breast cancer (BC) patients from a previous Phase III GOIM 9902 trial adjuvant taxanes. At median follow-up 64 months, original study showed no disease-free survival (DFS) or overall (OS) differences with addition docetaxel (D) to epirubicine-cyclophosphamide (EC). Immunohistochemistry was employed assess expression DDR phosphoproteins (pATM, pATR, pCHK1, γH2AX, pRPA32, pWEE1) tumor tissue, their association clinical outcomes evaluated through Cox elastic net model. Over an extended 234 we confirmed significant DFS OS between treated EC those receiving D → EC. A risk score, inversely driven by ATM ATR expression, emerged as independent prognostic factor for both (HR = 0.41,

Language: Английский

Unlocking the molecular mechanisms of anticancer and immunomodulatory potentials of cariprazine in triple negative breast cancer DOI Open Access
Aleksandar Lazovic, Bojana Simović Marković,

Irfan Ćorović

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2025, Volume and Issue: 184, P. 117931 - 117931

Published: Feb. 19, 2025

Language: Английский

Citations

1
Key players inducing skin diseases and skin aging and potential preventive or therapeutic strategies using phytochemicals DOI Creative Commons
Hamid M. Abdolmaleky, Jin‐Rong Zhou

Deleted Journal, Journal Year: 2025, Volume and Issue: unknown, P. 100073 - 100073

Published: Feb. 1, 2025

Language: Английский

Citations

0
Probiotics and gut microbiota modulation: implications for skin health and disease management DOI

Elahe Parhizkar,

Parisa Vosough,

Maryam Baneshi

et al.

Archives of Microbiology, Journal Year: 2025, Volume and Issue: 207(3)

Published: Feb. 23, 2025

Language: Английский

Citations

0
Therapeutic potential of dopamine and serotonin in inflammation and cancer: Insights into immune regulation DOI

Hamid Norioun,

Ramin Hossein Baki,

Saeedeh Ghiasvand

et al.

Neuroscience, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 1, 2024

Language: Английский

Citations

1
DNA Damage Response in Early Breast Cancer: A Phase III Cohort in the Phobos Study DOI Open Access
Eriseld Krasniqi, Cristiana Ercolani, Anna Di Benedetto

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(15), P. 2628 - 2628

Published: July 23, 2024

We assessed the impact of DNA damage response and repair (DDR) biomarker expressions in 222 node-positive early breast cancer (BC) patients from a previous Phase III GOIM 9902 trial adjuvant taxanes. At median follow-up 64 months, original study showed no disease-free survival (DFS) or overall (OS) differences with addition docetaxel (D) to epirubicine-cyclophosphamide (EC). Immunohistochemistry was employed assess expression DDR phosphoproteins (pATM, pATR, pCHK1, γH2AX, pRPA32, pWEE1) tumor tissue, their association clinical outcomes evaluated through Cox elastic net model. Over an extended 234 we confirmed significant DFS OS between treated EC those receiving D → EC. A risk score, inversely driven by ATM ATR expression, emerged as independent prognostic factor for both (HR = 0.41,

Language: Английский

Citations

0